Close Menu

Jonathan MacQuitty, president of Abingworth Management, oversees the venture capital company’s investments in life sciences, which include Aurora Biosciences, Entelos, Pharmacopeia, and Solexa. He has served on the board of the Biotechnology Industry Organization and was an industry insider for years before heading to the finance side. GT’s Meredith Salisbury chatted with MacQuitty to get the skinny on what the genomics investment world looks like right now, and where it’s heading.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.